Current Advances in Paper-Based Biosensor Technologies for Rapid COVID-19 Diagnosis
1Center for Convergent Research of Emerging Virus Infection, Korea Research Institute of Chemical Technology, Daejeon, 34114 Republic of Korea.
Biochip Journal
|August 15, 2022
Summary
This review explores paper-based diagnostic platforms for rapid COVID-19 detection. Future advancements aim for highly sensitive, accurate, and cost-effective point-of-care tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Area of Science:
- Biomedical Engineering
- Infectious Diseases
- Diagnostic Technologies
Background:
- The COVID-19 pandemic necessitates rapid, accessible diagnostic tools beyond PCR.
- Current point-of-care tests for SARS-CoV-2 face challenges in cost, speed, and accuracy.
- Understanding SARS-CoV-2 structure and biomarkers is crucial for diagnostic development.
Purpose of the Study:
- To review paper-based diagnostic platforms for COVID-19 detection.
- To discuss limitations of current paper-based devices.
- To explore novel technologies enhancing paper-based diagnostics.
Main Methods:
- Literature review of SARS-CoV-2 diagnostics.
- Analysis of paper-based diagnostic platforms and detection mechanisms.
- Investigation of emerging technologies like nanotechnology, aptamers, SERS, and CRISPR-Cas.
Main Results:
- Paper-based diagnostics offer potential for low-cost, rapid COVID-19 testing.
- Current devices exhibit performance limitations.
- Integration with advanced technologies can significantly improve sensitivity and accuracy.
Conclusions:
- Novel paper-based platforms show promise for improved point-of-care COVID-19 diagnostics.
- Further development is needed to overcome existing limitations.
- Future diagnostics should prioritize sensitivity, accuracy, cost-effectiveness, and ease of use.
Keywords:
COVID-19Lateral flow assay (LFA)Paper-based biosensorsPoint-of-care testing (POCT)SARS-CoV-2
